Market Overview

UPDATE: Cantor Fitzgerald Initiates Buy, $43 on Walgreen Post Express Scripts Contract Resolution

Related WAG
CVS Health Corp Outperforms Key Peers In 2014
CVS Health Corp Shares Strongest Performer In Drug Retail Space
Will the Prez Call Out…The Oracle? (Fox Business)

Cantor Fitzgerald initiated its coverage on Walgreen (NYSE: WAG) with a Buy rating and a price target of $43.

Cantor Fitzgerald noted, "We expect 50% recovery of the lost script volume by FY:13. The combination of synergies from Alliance Boots, impact from generics, contribution from the USA Drug acquisition, and the benefits of an aging store fleet should be accretive by close to $0.30 per share in FY:13. We prefer to be conservative in our assumptions for ESRX and assume that marketing expenses are likely to offset $0.11-$0.12 per share benefit from recaptured ESRX scripts in FY:13. If customer re-activation costs are lower than our expectations, or if Walgreen's is able to recapture a higher portion of ESRX customers relative to our assumption, we see potential for further upside.."

Walgreen closed at $35.44 on Tuesday.

Latest Ratings for WAG

DateFirmActionFromTo
Sep 2014BarclaysDowngradesOverweightEqual-weight
Aug 2014Bank of AmericaUpgradesUnderperformNeutral
Aug 2014Cantor FitzgeraldUpgradesSellHold

View More Analyst Ratings for WAG
View the Latest Analyst Ratings

Posted-In: Cantor FitzgeraldAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (WAG)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters